摘要
目的：通过荟萃分析系统评价中医疏肝健脾法与西医常规疗法治疗腹泻型肠易激综合征（IBS-D）的临床疗效。方法：计算机检索从建库至2015年5月中国科技期刊数据库（维普）、万方数字化期刊全文数据库、中国期刊全文数据库（CNKI）有关疏肝健脾法治疗IBS-D的临床随机对照研究文献,采用Review Manager 5.2软件对纳入的研究进行荟萃分析。结果：符合纳入标准的文献共29篇,包括2611例患者。有效率分析：中医疏肝健脾法治疗IBS-D的有效率为91.87%,西医组的有效率为69.03%,荟萃分析显示各组间无异质性P=0.99,I2=0,采用固定效应模型合并分析提示,中医疏肝健脾法治疗IBS-D的有效率优于西医疗法（OR=5.28,95%CI：4.19～6.64）。治愈率分析：中医疏肝健脾法治疗IBS-D的治愈率为31.63%,西医组的治愈率为17.18%,荟萃分析显示各组间无异质性P=0.90,I2=0,采用固定效应模型合并分析提示,中医疏肝健脾法治疗IBS-D治愈率优于西医疗法（OR=2.30,95%CI：1.85～2.87）。结论：中医疏肝健脾法治疗IBS-D的有效率、治愈率均优于西医常规疗法。由于纳入文献质量偏低,仍需进一步的高质量临床随机对照研究证实。
Objective：To compare the clinical efficacy of traditional Chinese medicine（Shugan jianpi）with conventional Western medicine for diarrhea-predominant irritable bowel syndrome（IBS-D）.Methods：We searched the VIP,Wanfang,and CNKI databases to identify the randomized controlled studies about Shuganjianpi for the treatment of IBS-D（up to May 2015）. These meta-analyses were performed by Review Manager 5.2 software. Results：Twenty-nine studies with a total of 2611 patients were included in this paper. The therapeutic effectiveness rate was 91.87% and 69.03% in Shuganjianpi group and Western medicine group,respectively. No heterogeneity was identified among the studies（P=0.99,I2=0）. Using a fixed effect model,shugan jianpi group was significantly superior to Western medicine group（OR=5.28,95% CI：4.19～6.64）. The cure rate was 31.63% and 17.18% in shugan jianpi and conventional Western groups,respectively. No heterogeneity was identified among the studies（P=0.90,I2=0）. Using a fixed effects model,shugan jianpi group was significantly superior to Western medicine group（OR=2.30,95%CI：1.85～2.87）. Conclusion：Shugan jianpi was better than Western conventional therapy for the treatment of IBS-D in terms of therapeutic effectiveness and cure. However,due to the poor quality of the included studies,further high-quality randomized controlled clinical trials should be needed.
出处
《辽宁中医药大学学报》
CAS
2016年第5期183-186,共4页
Journal of Liaoning University of Traditional Chinese Medicine
